An experimental cholesterol-lowering drug called Alirocumab from Sanofi and Regeneron Pharmaceuticals significantly reduced bad cholesterol levels in four ongoing trials. An analysis also showed the drug could reduce risks for premature death, stroke, heart attack and hospitalization.